Following positive results from the Phase 1 dose escalation study, BND-22 (SAR444881) is now being tested in Phase 2 trials as monotherapy for patients ...

Through the interactions, macrophages make the immunosuppressive microenvironment proinflammatory, enabling immune attacks on cancer cells and enhancing the effectiveness of checkpoint inhibitors ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

ES019 targets two checkpoint inhibitors – PD-L1 and SIRP ... has shown evidence that it can stimulate “highly potent” phagocytosis in lab studies. Drugs targeting the SIRP-alpha/CD47 axis ...

Add articles to your saved list and come back to them any time.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Search for other works by this author on: ...

Department of Chemistry, University of Chicago, 929 East 57th Street, Chicago, Illinois 60637, United States Department of Radiation and Cellular Oncology and Ludwig Center for Metastasis Research, ...

After hours: February 28 at 5:53:09 PM EST Loading Chart for CHKP ...